Global Managed Access Program Cohort for Remibrutinib in Adult Patients With Chronic Spontaneous Urticaria

Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.

NCT06042478 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.

NCT05795153 ·Status: COMPLETED ·Phase: PHASE3

Global Managed Access Program Cohort for Ligelizumab in CSU

NCT04903613 ·Status: NO_LONGER_AVAILABLE

A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

NCT06868212 ·Status: RECRUITING ·Phase: PHASE3

A Study of MTPS9579A in Participants With Refractory Chronic Spontaneous Urticaria

NCT05129423 ·Status: WITHDRAWN ·Phase: PHASE2

A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria

NCT07316114 ·Status: RECRUITING

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

NCT05677451 ·Status: RECRUITING ·Phase: PHASE3

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

NCT05976243 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study of Quilizumab Versus Placebo in Patients With Refractory Chronic Spontaneous Urticaria

NCT01987947 ·Status: COMPLETED ·Phase: PHASE2

A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

NCT07219615 ·Status: RECRUITING ·Phase: PHASE2

Safety Study of Rituximab (Rituxan®) in Chronic Urticaria

NCT00216762 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)

NCT04681729 ·Status: COMPLETED ·Phase: PHASE3

Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria

NCT06795373 ·Status: WITHDRAWN ·Phase: PHASE2

A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines

NCT03580369 ·Status: COMPLETED ·Phase: PHASE3

A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.

NCT03580356 ·Status: COMPLETED ·Phase: PHASE3

A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria

NCT05528861 ·Status: TERMINATED ·Phase: PHASE2

Study to Evaluate the Efficacy, Safety, and Tolerability of Tirabrutinib in Participants With Antihistamine-Resistant Chronic Spontaneous Urticaria

NCT04827589 ·Status: WITHDRAWN ·Phase: PHASE2

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

NCT06455202 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment

NCT02550106 ·Status: COMPLETED ·Phase: PHASE4

Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)

NCT04180488 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment

NCT06228560 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study

NCT03693625 ·Status: TERMINATED ·Phase: PHASE2

A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria

NCT04159701 ·Status: TERMINATED ·Phase: PHASE2

Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU

NCT02477332 ·Status: COMPLETED ·Phase: PHASE2

A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients

NCT02649218 ·Status: COMPLETED ·Phase: PHASE2